BRISTOL-MYERS SQUIBB COMPANY Sales Revenue, Goods, Gross (Deprecated 2018-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Sales Revenue, Goods, Gross (Deprecated 2018-01-31) of $7.68 billion for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsGross · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $7.68B, a 17.18% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $7.51B, a 19.08% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $6.70B, a 14.31% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $6.55B.
| Period end | Sales Revenue, Goods, Gross (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Gross (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Gross (Deprecated 2018-01-31) 9 month |
|---|---|---|---|
| 2018-09-30 | $7.68B 10-Q · filed 2018-10-25 | $15.19B derived: sum of 2 quarters · filed 2018-10-25 | $21.89B 10-Q · filed 2018-10-25 |
| 2018-06-30 | $7.51B 10-Q · filed 2018-07-26 | $14.21B 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $6.70B 10-Q · filed 2018-04-26 | ||
| 2017-09-30 | $6.55B 10-Q · filed 2018-10-25 | $12.86B derived: sum of 2 quarters · filed 2018-10-25 | $18.72B 10-Q · filed 2018-10-25 |
| 2017-06-30 | $6.31B 10-Q · filed 2018-07-26 | $12.17B 10-Q · filed 2018-07-26 | |
| 2017-03-31 | $5.86B 10-Q · filed 2018-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |